Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2853-2860

  Bailly, Christian ^a   Dassonneville, Laurent ^a   Colson, Pierre ^b   Houssier, Claude ^b   Fukasawa, Kazuhiro ^c   Nishimura, Susumu ^c   Yoshinari, Tomoko ^c  

^a INSERM   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; DNA TOPOISOMERASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DNA BINDING; DNA CLEAVAGE; DNA FOOTPRINTING; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTERCALATION COMPLEX; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBAZOLES; DNA; DNA FOOTPRINTING; DNA TOPOISOMERASES, TYPE I; DRUG DESIGN; GLUCOSIDES; HUMANS; INHIBITORY CONCENTRATION 50; INTERCALATING AGENTS; MICE; STEREOISOMERISM; TUMOR CELLS, CULTURED;

EID: 0033564429     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Arakawa, H., Iguchi, T., Morita, M., Yoshinari, T., Kojiri, K., Suda, H., Okura, A., and Nishimura, S. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Res., 55: 1316-1320, 1995.
2. Kojiri, K., Kondo, H., Yoshinari, T., Arakawa, H., Nakajima, S., Satoh, F., Kawamura, K., Okura, A., Suda, H., and Okanishi, M. A new antitumor substance BE-13793C, produced by a streptomycete. Taxonomy, fermentation, isolation, structure determination and biological activity. J. Antibiot. (Tokyo), 44: 723-728, 1991.
3. Yoshinari, T., Yamada, A., Uemura, D., Nomura, K., Arakawa, H., Kojiri, K., Yoshida, E., Suda, H., and Okura, A. Induction of topoisomerase 1-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res., 53: 490-494, 1993.
4. Arakawa, H., Iguchi, T., Yoshinari, T., Kojiri, K., Suda, H., and Okura, A. ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice. Jpn. J. Cancer Res., 84: 574-581, 1993.
5. Kanzawa, F., Nishio, K., Kubota, N., and Saijo, N. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res., 55: 2806-2813, 1995.
6. Vanhoefer, U., Voigt, W., Hilger, R. A., Yin, M-B., Harstrick, A., Seeber, S., and Rustum, Y. M. Cellular determinants of resistance to indolocarbazole analogue NB-506. A novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Oncol. Res., 9: 485-494, 1997.
7. Ohe, Y., Tanigawara, Y., Fujii, H., Ohtsu, T., Wakita, H., Igarashi, T., Minami, H., Eguchi, K., Shinkai, T., Tamura, T., Kunotoh, H., Saijo, N., Okada, K., Ogino, H., and Sasaki, Y. Phase I and pharmacology study of 5-day infusion of NB-506. Proc. ACSO, 16: 199a, 1997.
8. Saijo, N. New chemotherapeutic agents for the treatment of non-small cell lung cancer. Chest, 113: 17S-23S, 1998.
9. Yamashita, Y., Fujii, N., Murakata, C., Ashizawa, T., Okabe, M., and Nakano, H. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry, 31: 12069-12075, 1992.
10. Yoshinari, T., Matsumoto, M., Arakawa, H., Okada, H., Noguchi, K., Suda, H., Okura, A., and Nishimura, S. Novel antitumor indolocarbazole compound 6-N-formylamino-12, 13-dihydro-1, 11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c] carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res., 55: 1310-1315, 1995.
11. Anizon, F., Belin, L., Moreau, P., Sancelme, M., Voldoire, A., Prudhomme, M., Ollier, M., Sevère, D., Riou, J-F., Bailly, C., Fabbro, D., and Meyer, T. Syntheses and biological activity (topoisomerases inhibition, antitumoral and antimicrobial proper-ties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem., 40: 3456-3465, 1997.
12. Bailly, C., Riou, J-F., Colson, P., Houssier, C., Rodrigues-Pereira, E., and Prudhomme, M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry, 36: 3917-3929, 1997.
13. Bailly, C., Colson, P., Houssier, C., Rodrigues-Pereira, E., Prudhomme, M., and Waring, M. J. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol. Pharmacol., 53: 77-87, 1998.
14. Bailly, C., Qu, X., Graves, D. E., Prudhomme, M., and Chaires, J. B. Calories from carbohydrates. Energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition. Chem. Biol., 6: 277-286, 1999.
15. Rodrigues-Pereira, E., Belin, L., Sancelme, M., Prudhomme, M., Ollier, M., Rapp, M., Sevère, D., Riou, J-F., and Fabbro, D. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J. Med. Chem., 39: 4471-4477, 1996.
16. Moreau, P., Anizon, F., Sancelme, M., Prudhomme, M., Bailly, C., Ollier, M., Sevère, D., Riou, J-F., Fabbro, D., Meyer, T., and Aubertin, A-M. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. J. Med. Chem., 42: 584-592, 1999.
17. Anizon, F., Moreau, P., Sancelme, M., Voldoire, A., Prudhomme, M., Ollier, M., Sevère, D., Riou, J-F., Bailly, C., Fabbro, D., Meyer, T., and Aubertin, A-M. Synthese, biochemical and biological evaluation of staurosporine analogs from the microbial metabolite rebeccamycin. Bioorg. Med. Chem., 66: 1597-1604, 1998.
18. Ohkubo, M., Nishimura, T., Jona, H., Honma, T., and Morishima. H. Practical synthesis of indolopyryrrolocarbazoles. Tetrahedron, 52: 8099-8112, 1996.
19. Ohkubo, M., Nishimura, T., Jona, H., Honma, T., Ito, S., and Morishima, H. Synthesis of dissymetric indolocarbazole glycosides using the Mitsunobu reaction at the glycosylation step. Tetrahedron, 53: 5937-5950, 1997.
20. Ohkubo, M., Kawamoto, H., Ohno, T., Nakano, M., and Morishima, H. Synthesis of NB-506, a new anticancer agent. Tetrahedron, 53: 585-592, 1997.
21. Baguley, B. C., Denny, W. A., Atwell, G. J., and Cain, B. F. Potential antitumor agent. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilino-acridines substituted in the anilino ring. J. Med. Chem., 24: 170-177, 1981.
22. Houssier, C., and O'Konski, C. T. Electro-optical instrumentation systems with their data acquisition and treatment. In: S. Krause (ed.), Molecular Electro-Optics, pp. 309-339. New York: Plenum Publishing Corporation, 1981.
23. Houssier, C. Investigating nucleic acids, nucleoproteins, polynucleotides, and their interactions with small ligands by electro-optical systems. In: S. Krause (ed.), Molecular Electro-Optics, pp. 363-398. New York: Plenum Publishing Corporation, 1981.
24. Colson, P., Bailly, C., and Houssier, C. Electric linear dichroism as a new tool to study sequence preference in drug binding to DNA. Biophys. Chem., 58: 125-140, 1996.
25. Bailly, C., Hénichart, J-P., Colson, P., and Houssier, C. Drug-DNA sequence-dependent interactions analyzed by electric linear dichroism. J. Mol. Recognit., 5: 155-171, 1992.
26. Bailly, C., and Waring, M. J. Comparison of different footprinting methodologies for detecting binding sites for a small ligand on DNA. J. Biomol. Struct. Dyn., 12: 869-898, 1995.
27. Pommier, Y., Covey, J. M., Kerrigan, D., Markovits, J., and Pharm, R. DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res., 15: 6713-6731, 1987.
28. Drew, H. R., Weeks, J. R., and Travers, A. A. Negative supercoiling induces spontaneous unwinding of bacterial promoter. EMBO J., 4: 1025-1032, 1985.
29. Larsen, A. K., Grondard, L., Couprie, J., Desoize, B., Comoe, L., Jardillier, J. C., and Riou, J. F. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem. Pharmacol., 46: 1403-1412, 1993.
30. Skehan, P., Storeng, R., Scudiero, D., Monks, A., MaMahon, J., Vistica, D., Warren, J. T., Bokesch, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
31. Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against diverse panel of human tumor cell lines. J. Natl. Cancer Inst., 82: 1113-1118, 1990.
32. Pommier, Y., Pourquier, P., Fan, Y., and Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400: 83-106, 1998.
33. Pommier, Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie, 80: 255-270, 1998.
34. Fukasawa, K., Komatani, H., Hara, Y., Suda, H., Okura, A., Nishimura, S., and Yoshinari, T. Sequence-selective cleavage by a topoisomerase I poison, NB-506. Int. J. Cancer, 75: 145-150, 1998.
35. Yang, D., Strode, J. T., Spielmann, H. P., Wang, A. H-J., and Burke, T. G. DNA interaction of two clinical camptothecin drugs stabilize their active lactone forms. J. Am. Chem. Soc., 120: 2979-2980, 1998.